Showing 7811-7820 of 9938 results for "".
- Ichthyosis Linked to Mood Disordershttps://practicaldermatology.com/news/ichthyosis-linked-to-mood-disorders/2462139/People living with Ichthyosis may be at higher risk for mental health conditions like depression and anxiety, according to a recent study in the Journal of the American Academy of Dermatology. Re
- ACAAI News: 72% of AD Patients Report Poor Mental Health for 1-10 Days in the Past Monthhttps://practicaldermatology.com/news/acaai-news-72-of-ad-patients-report-poor-mental-health-for-1-10-days-in-the-past-month/2462129/Folks with atopic dermatitis (AD) are more likely to report poor mental health than their counterparts without the inflammatory skin condition, new research shows. The study, which was presented at the 2023 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientif
- CeraVe Launches in Indiahttps://practicaldermatology.com/news/cerave-launches-in-india/2462126/L'Oréal Dermatological Beauty recently unveiled CeraVe in India. To support the launch, the brand hosted 'Skin Barrier Science - A Dermatological Summit' in Mumbai, with dermatologists, experts, and partners from all over India and t
- Updated AAD Guidelines on AD in Adults Back Use of Biologics, JAK Inhibitorshttps://practicaldermatology.com/news/updated-aad-guidelines-on-ad-in-adults-back-use-of-biologics-jak-inhibitors/2462123/Updated American Academy of Dermatology (AAD) guidelines on systemic treatment of atopic dermatitis (AD) in adults strongly back the use of dupilumab, tralokinumab, abrocitinib, baricitinib, and upadacitinib. “When the last guidelines were published in 2014, only no
- TNF Blockers Are Not Associated With Poor Pregnancy Outcomeshttps://practicaldermatology.com/news/tnf-blockers-are-not-associated-with-poor-pregnancy-outcomes/2462122/Continuing tumor necrosis factor (TNF) inhibitors during pregnancy is not associated with worse fetal or obstetric outcomes and may reduce the risk of severe maternal infections during pregnancy, according to research presented at ACR Convergence 2023, the American College of Rheumatology&r
- In the Lab With Boston University Melanoma Researcher Deborah Langhttps://practicaldermatology.com/news/in-the-lab-with-boston-university-melanoma-researcher-deborah-lang-phd/2462120/Deborah Lang, PhD, associate professor of dermatology at Boston University Chobanian & Avedisian School of Medicine, received a two-year, $300,000 Discovery Boost Grant from the American Cancer Society (ACS) for her research project “Exploring roles for PAX3 in regulating gene expressio
- Ventyx Biosciences Halts Trial for Experimental Psoriasis Drughttps://practicaldermatology.com/news/ventyx-biosciences-halts-trial-for-experimental-psoriasis-drug/2462116/Ventyx Biosciences has announced it is halting development of an experimental psoriasis drug due to missed internal targets required for it to advance beyond Phase 2, according to the company. The drug, VTX958, had shown acceptable safety and efficacy, and had achevied with its 225 mg B
- ASDS Elects New Board at Annual Membership Meetinghttps://practicaldermatology.com/news/asds-elects-new-board-at-annual-conference/2462114/The American Society for Derm
- FDA Approves Cosentyx for HShttps://practicaldermatology.com/news/fda-approves-cosentyx-for-hs/2462109/The US Food and Drug Administration (FDA) has given its nod to Novartis’ Cosentyx (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. The IL-17A inhibitor is the first new biologic treatment option for HS patients in nearly a decade.</
- Healiva, C4U Join Forces to Develop New Gene Therapy for EBhttps://practicaldermatology.com/news/healiva-c4u-join-forces-to-develop-new-gene-therapy-for-eb/2462106/Healiva SA (Healiva) and C4U Corporation (C4U) have entered into a strategic alliance agreement regarding the development of CRISPR-Cas3 derived therapeutic solutions for Epidermolysis Bullosa (EB), also known as “butterfly children”. “The collaboration aims to provide